Alternative routes of measles immunization: A review

Biologicals

Volumn 25, Issue 3, 1997, Pages 323-338

  Cutts, F T ^a   Clements, C J ^b   Bennett, J V ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CARTER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ADOLESCENT; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; HUMAN; IMMUNE RESPONSE; INFANT; INFECTION CONTROL; INHALATIONAL DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; MEASLES; MEASLES VACCINATION; META ANALYSIS; NEEDLE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE;

EID: 0031237124     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0103     Document Type: Article

References (56)

1. 1. Bloch AB, Orenstein WA, Ewing WM et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75: 676-683.
2. 2. Sabin AB. My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics 1992; 90: 162-169.
3. 3. Anon. Role of mass campaigns in global measles control. Lancet 1994; 344: 174-175.
4. 4. de Quadros C, Olive J, Hersh B et al. Measles elimination in the Americas - evolving strategies. J Am Med Assoc 1996; 275: 224-229.
5. 5. Aylward B, Lloyd J, Zaffran M et al. Reducing the risk of unsafe injections in immunization programmes: the financial and operational implications of using different injection technologies. Bull WHO 1995; 73(4): 531-540.
6. 6. Anon. Safety of injections in immunization programmes. WHO recommended policy. WHO/EPI/HIS/ 97.1 WHO, Geneva, Switzerland.
7. 7. Amler RW, Orenstein WA, Bart KJ. Aerosolized measles vaccine - will it open the window? Rev Inf Dis 1983; 5(3): 524-526.
8. 8. Sabin A, de Castro JF, Arechiga A et al. Clinical trial of inhaled aerosol of human diploid and chick embryo measles vaccines. Lancet 1982; ii: 604.
9. 9. Sabin A, Arechiga A, de Castro JF et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. J Am Med Assoc 1983; 249: 2651-2662.
10. 10. Sabin A, Arechiga A, De Castro JF et al. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine II. Vaccine comparisons and evidence for multiple antibody response. J Am Med Assoc 1984; 251: 2363-2371.
11. 11. Beck M, Smerdel S, Dedic I et al. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Standard 1986; 65: 95-100.
12. 12. Smerdel S. Clinical trials in Yugoslavia. Workshop on the use of measles vaccine in children under 9 months of age. Centers for Disease Control, Atlanta, Georgia. November 21-22, 1985.
13. 13. Aaby P, Clements CJ. Measles immunization research: a review. Bull WHO 1989; 67: 443-448.
14. 14. Cutts F, Grabowsky M, Markowitz L. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23: 95-106.
15. 15. Diaz-Ortega JL, Forsey T, Clements CJ et al. The relationship between dose and response of standard measles vaccines. Biologicals 1994; 22: 35-44.
16. 16. Cooper C, Morley D, Weeks M et al. Administration of measles vaccine by dermojet. Lancet 1966; i: 1076-1077.
17. 17. Hong Kong Measles Vaccine Committee. Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull WHO 1967; 36: 375-384.
18. 18. Burland, W. Measles vaccination by the intradermal route. Postgrad Med J 1969; 45: 323-326.
19. 19. Wood P, Soberanda K, Bracken P et al. Measles vaccination in Zaire - when and how? Trans R Soc Trop Med Hyg 1980; 74: 381-382.
20. 20. Kok P, Kenya P, Ensoring H. Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration. Trans R Soc Trop Med Hyg 1983; 77: 171-176.
21. 21. Whittle H, Rowland M, Mann G et al. Immunization of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984; i: 834-837.
22. 22. de Moraes J, Leon M, Souza V et al. Intradermal administration of measles vaccines. Bulletin of PAHO 1994; 28: 250-255.
23. 23. McCrumb F. Studies with live attenuated measles virus vaccine: clinical and immunologic responses in institutionalized children. Am J Dis Children 1961; 101: 45-56.
24. 24. Cernescu C, Cajal N. Antimeasles vaccination by natural routes - experimental background and practical consequences. Rev Roum Med-Virol 1984; 35: 259-271.
25. 25. Black F, Sheridan S. Studies on an attenuated measles-virus vaccine. N Engl J Med 1960; 263: 165-169.
26. 26. Bennett J, de Castro F, Delgadillo C et al. Pilot study of administering Edmonston-Zagreb measles vaccine by alternate routes in 5-month-old children, Guadalajara, Mexico 1990 (unpublished).
27. 27. Whittle H, Rowland M, Mann G. Failure of measles vaccine sprayed into the oropharynx of infants. Lancet 1983; i: 1045.
28. 28. Kress, S, Schluederberg A, Hornick R et al. Studies with live attenuated measles-virus vaccine. Amer J Dis Children 1961; 101: 57-63.
29. 29. McCrumb F, Bulkeley J, Hornick R et al. Clinical trials with living attenuated measles virus vaccines. Am J Public Health 1962; 52: 11-15.
30. 30. Terskikh A, Danilov A, Sheltchkov G et al. Theoretical substantiation and effectiveness of immunization with aerosols of liquid measles vaccine. Vesta Akad Med Narek USSR 1971; 26: 84-90.
31. 31. Vlatkovic R, Smerdel S, Gvojic B et al. Intranasal administrtion of chick embryo fibroblast Edmonston-Zagreb measles vaccine. Lancet 1985; i: 520.
32. 32. Sabin A. Immunization against measles by aerosol. Rev Infect Dis 1983; 5: 514-523.
33. 33. Simasathien S, Migasena S, Bellini W et al. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine 1997; 15: 329-334.
34. 34. Okuno Y. Vaccination with egg passage measles virus by inhalation. Am J Dis Children 1962; 103: 211-214.
35. 35. Okuno Y, Ueda S, Hosai H et al. Studies on the combined use of killed and live measles vaccines II. Advantages of the inhalation method. Biken J 1965; 8: 81-85.
36. 36. Ueda S, Hosai H, Minekawa Y et al. Studies on the combined use of killed and live measles vaccine III. Conditions for the "take" of live vaccine. Biken J 1966; 9: 97-101.
37. 37. Danilov A. The basis for vaccination against measles by aerosols of live vaccine. In JFP Hers and KC Winkler (eds) Airborne transmission and airborne infection. John Wiley and Sons, New York, 1973; 344-345.
38. 38. Sabin A, Albrecht P, Takeda A et al. High effectiveness of aerosolized chick embryo fibroblast vaccine in seven-month-old and older infants. J Infect Dis 1985; 152: 1231-1237.
39. 39. Torigoe S, Biritwum R, Isomura S et al. Measles in Ghana: a trial of an alternative means of administration of measles vaccine. J Trop Pediatr 1986; 32: 304-309.
40. 40. de Castro JF, Gomez JL, Diaz-Ortega JL et al. Diploid cell measles vaccine. J Am Med Assoc 1986; 256: 714.
41. 41. de Castro JF, Kumate J. La vacunacion contra el sarampion. Situacion en Mexico e America. Avances en el metodo de immunizacion por aerosol. Bol Med Hosp Infant Mex 1990; 47: 449-461.
42. 42. de Castro JF, Kumate J, Sepulveda J et al. La vacunacion antisarampionosa en Mexico por el metodo de aerosol. Solud Publica Mex 1997; 39: 53-60.
43. 43. Fernandez-Bracho JG, Roldan-Fernandez SG. Reacciones tempranas en escolares vacunados con antisarampionosa en aerosol. Salud Publica Mex 1990; 32: 653-657.
44. 44. Khanum S, Uddin N, Garelick H et al. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987; i: 150-153.
45. 45. Ekunwe E. Immunization by inhalation of aerosolized measles vaccine. Annals Trop Pediatr 1990; 10: 145-149.
46. 46. Krober M, Stracener C, Bass J et al. Decreased measles antibody response after measles-mumps-rubella vacine in infants with colds. J Am Med Assoc 1991; 265: 2095-2096.
47. 47. Cutts F, Nyandu B, Markowitz L et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3·5 month-old infants, and of medium or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasha, Zaire. Vaccine 1994; 12: 1311-1313.
48. 48. Cutts F, Mandala K, St. Louis M et al. Immunogenicity of high titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasha, Zaire. J Infect Dis 1993; 167: 1418-1421.
49. 49. Dennehy P, Saracen C, Georges P. Seroconversion rates to confirmed measles-mumps-rubella-varicella vaccine of children with upper respiratory infection. Pediatrics 1994; 94: 514-516.
50. 50. Halsey N, Bondos R, Mode F et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985; 313: 544-549.
51. 51. Ratnam S, West R, Gada V et al. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127: 432-436.
52. 52. King G, Markowitz L, Heath J et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. J Am Med Assoc 1996; 275: 704-707.
53. 53. Cilia G, Pena B, Marimon J et al. Serologic responses to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Vaccine 1996; 14: 492-494.
54. 54. Ogra P, Fishaut M, Gallagher M. Viral vaccination via the mucosal routes. Rev Infect Dis 1980; 2: 352-369.
55. 55. Banatvala J, Best J, O'Shea S et al. Rubella-immunity gap: is intranasal vaccination the answer? Lancet 1979; i: 970.
56. 56. O'Shea S, Best J, Banatvola J. Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccinees. J Infect Dis 1985; 151: 89-90.